BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) is a global biotechnology company that develops and commercializes medicines for people with genetically defined rare diseases. Its marketed therapies include VOXZOGO for achondroplasia and enzyme therapies VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA and KUVAN; it… From the company’s description.
Over the twelve months to Sep 30, 2026, BioMarin Pharmaceutical Inc. reported revenue of $3.66B, up 18.1% from a year earlier, and a net loss of $19.11M. Its operating margin was 3.1%, and operations generated $676.62M in cash. In fiscal 2025, it reported revenue of $3.22B, up 12.9% from fiscal 2024, and net income of $348.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BioMarin Pharmaceutical Inc. does
In the company’s own words
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) is a global biotechnology company that develops and commercializes medicines for people with genetically defined rare diseases. Its marketed therapies include VOXZOGO for achondroplasia and enzyme therapies VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA and KUVAN; it also has clinical and preclinical programs targeting genetic conditions. The company’s commercial organization is structured around Skeletal Conditions, centered on VOXZOGO, and Enzyme Therapies. It sells directly to specialty pharmacies, hospitals, government agencies and other end-users, and also uses distributors and pharmaceutical wholesalers; Sanofi distributes and sells ALDURAZYME worldwide. BioMarin’s products address conditions including achondroplasia, mucopolysaccharidosis, phenylketonuria and CLN2 disease. The company reported $3.2 billion in total revenue in 2025. It was founded in 1997 and completed its acquisition of Inozyme Pharma in 2025, adding the clinical-stage enzyme therapy candidate BMN 401 to its portfolio.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NOVATO, CA
- Fiscal year end
- December
- CIK
- 1048477
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioMarin Pharmaceutical Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioMarin Pharmaceutical Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
BioMarin Pharmaceutical Inc.’s bonds, as funds hold them
Funds report holding 3 issues of BioMarin Pharmaceutical Inc.’s debt, $397.80M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.87%, maturing 2027 to 2034.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioMarin Pharmaceutical Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioMarin Pharmaceutical Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioMarin Pharmaceutical Inc.'s last four quarterly filings that the numbers alone won't show?”